Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Enveric Biosciences, Inc. ENVB NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
37/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Enveric Biosciences, Inc. (ENVB) is a Biotechnology company in the Healthcare sector, currently trading at $1.95. It has a SharesGrow Score of 35/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Valuation: ENVB trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25).

Net income is $12M (loss), growing at -18399.7%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $4M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 5.38 (strong liquidity). Debt-to-assets is 0%. Total assets: $5M.

Analyst outlook: 3 / 4 analysts rate ENVB as buy (75%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 75/100 (Pass), Income ?/100 (Fail).

ENVB SharesGrow Score Overview

46/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 75/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ENVB

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
ENVB: +0%/yr revenue is, -18399.7%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ENVB: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 5.38 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ENVB: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
75/100
Analyst outlook: 3 / 4 analysts rate ENVB as buy (75%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.75-17.844
Volume21.46K
Avg Volume (30D)364.5K
Market Cap$1.16M
Beta (1Y)0.33
Share Statistics
EPS (TTM)-36.24
Shares Outstanding$334.72K
IPO Date2015-05-04
Employees5
CEOJoseph Edward Tucker
Financial Highlights & Ratios
Gross Profit$-200.86K
EBITDA$-8.57M
Net Income$-12.13M
Operating Income$-8.77M
Total Cash$4.68M
Net Debt$-4.68M
Total Assets$5.1M
Price / Earnings (P/E)-0.1
Analyst Forecast
Rating ConsensusBuy
Analysts Covering4
Buy 75% Hold 25% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS29405E5050

Price Chart

Track all markets on TradingView
ENVB
Enveric Biosciences, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.75 52WK RANGE 17.84

People Also View

ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 ELEV
ELEV
Elevation Oncology, Inc.
$0.37
-2.12%
 AVRO
AVRO
AVROBIO, Inc.
$1.40
-1.41%
 CWBR
CWBR
CohBar, Inc.
$0.41
+0.00%
 HEPA
HEPA
Hepion Pharmaceuticals, Inc.
$0.05
+18.52%
 OCEA
OCEA
Ocean Biomedical, Inc.
$0.00
+0.00%
 EFTR
EFTR
eFFECTOR Therapeutics, Inc.
$0.00
+0.00%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message